01 Sep 2010

TREAT: Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin) Therapy

Topics: Acute Coronary Syndromes (ACS)
Session number: 711005 - 711006
Session title: Clinical Trial Update III
Authors: McMurray, John - Swedberg, Karl

	Presenter
	Presenter \| see Discussant report
McMurray, John (United Kingdom)

Abstract:

Over a median of 29 months, the primary outcome of death or a major cardiovascular event occurred in 632 patients. This presentation will describe the clinical predictors of the primary cardiovascular composite outcome in this extremely high risk population.

The multivariable analyses include standard cardiovascular and diabetes clinical variables (e.g. past CV history, history of diabetes complications e.g. neuropathy), metabolic and renal plasma and urinary biomarkers (e.g. HbA1c, eGFR, urinary albumin creatinine ratio) and novel biomarkers (including high-sensitivity troponin and natriuretic peptides) in this population.

	Discussant
	Discussant \| see Presenter abstract
Swedberg, Karl (Sweden)

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.